Latest news with #ChrisGibson
Yahoo
6 days ago
- Business
- Yahoo
Former NY Congressman releases new book on America's past and future
(WIVT/WBGH) – A former representative of New York's 19th District is out with a new book that looks back on how difficult decisions made during the founding of our country might offer guidance on how to deal with the deep divisions that exist today. Chris Gibson has published 'The Spirit of Philadelphia: A Call To Recover The Founding Principles.' The book is based on research Gibson did about the Constitutional Convention held in 1787 in Philadelphia to address some of the weaknesses in the Articles of Confederation. Gibson says the years between the Revolutionary War and the adoption of the Constitution was marked by a lot of dissent, dysfunction and open rebellion. Gibson says the framers of the Constitution purposely created checks and balances that decentralized power and gave control over lawmaking, funding, and the ability to go to war to the people's representatives in Congress. He says that over the past century, and even more so in recent times, power has steadily been consolidated in the president at the expense of Congress. 'Basically, you vote for a president, that president comes in, whether it's Barack Obama on the left or Donald Trump on the right, and the expectation for those voters is that they're going to get everything they're looking for and it's going to come by way of executive action. This is in part what changed how we interact with each other. By moving away from founding principles, we have really torn our social fabric and we're living with the consequences of those changing ideas,' said Gibson. Gibson, who spent three years as president of his alma mater, Siena College, says the convention in Philadelphia not only created a framework for the government but also a spirit of collaboration and optimism. He says, despite the divisions of today, most Americans still agree about the value of liberty and equality. You can find out more information and purchase the book at Gibson includes some of his recommendations for addressing our country's polarization and says he'd be happy to Zoom in with any book clubs interested in reading his book. Watch the full interview with Gibson below. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
06-05-2025
- Business
- Yahoo
Recursion axes drug programmes to streamline pipeline
AI business Recursion Pharmaceuticals has narrowed its drug development pipeline, ending or pausing five programmes as it seeks to reduce costs and reprioritise resources following a merger with fellow AI biotech Exscientia last year. The company's Q1 2025 earnings report revealed plans to cut three clinical programmes, pause one clinical candidate and cut a preclinical effort. Shares in Recursion fell by 13.4% on 5 May, dropping from $5.49 at market open to $4.76 at close following the pipeline restructuring announcement. The terminated programmes include REC-2282, REC-994, and REC-3964. REC-2282 and REC-994 were in development for rare neurological disorders – neurofibromatosis type 2 and cerebral cavernous malformation (CCM), respectively. According to Recursion, accumulated data from both trials did not justify continued investment. The company formally stated that the 'totality' of the results supported ending development altogether. REC-994 had reached Phase II testing in CCM. Data from the 62-patient trial (NCT05085561) was announced in September 2024, with a follow-up in February 2025. The trial showed comparable safety and tolerability to placebo over 12 months and met its primary endpoint, but did not demonstrate meaningful clinical benefits. MRI scans suggested a trend toward reduced lesion volume at the higher dose of 400mg, but no improvements were observed in patient-reported outcomes or functional assessments. Follow-up data, including a long-term extension phase, failed to confirm earlier signals of efficacy. Recursion is not fully discontinuing its REC-3964 programme – aimed at treating C difficile infection – but is instead exploring potential out-licensing opportunities. The company cited a shift in the treatment landscape and internal reprioritisation as reasons for reconsidering further development. In addition to these terminations, Recursion is pausing development of REC-4539, a clinical-stage oncology candidate. A preclinical programme in an undisclosed indication is also being discontinued. These changes leave Recursion with six active development programmes. Four of which are in oncology while two target rare diseases. None are currently in late-stage trials. 'The data is going to be ultimately what drives what the balance of the portfolio looks like, but I do not see us abandoning either oncology or rare disease in the near term,' said Recursion CEO Chris Gibson in a 5 May earnings call to investors. The pipeline restructuring follows a period of strategic realignment after Recursion's merger with Exscientia. Najat Khan, who serves as both chief R&D officer and chief commercial officer, said the company is making 'deliberate tradeoffs' to focus on areas of high unmet need and the greatest potential impact.
Yahoo
14-04-2025
- Science
- Yahoo
Evansville's New Tech Institute to hold send off for robotics team
HENDERSON, Ky (WEHT) – Evansville's New Tech Institute will hold a send off for their first robotics team as they attend the first world championship in Houston. The competition will start on Wednesday, and the public is invited to the event to wish the Thunderbots well this afternoon in the school's cafeteria. They advanced by winning the statewide Engineering Inspiration Award earlier this month in Greenwood. Senior Ava Roll and Principal Chris Gibson joined Daybreak to talk about the competition. We're told the team's robot, Dr. Smith, is already on the way to Houston. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
